Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies-Reference-Cited by-同舟云学术

Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies

Published:2023-01 Issue:1 Volume:18 Page:67-78
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dagogo-Jack Ibiayi,Abbattista Antonello,Murphy John F.,Krulewicz Stan,Do Andrew,Peterson Jennifer,Lin Jessica J.,Gainor Justin F.,Messina Rossella,Krueger Elizabeth A.,Thurm Holger,Yeap Beow Y.

Funder

Pfizer

Pfizer Inc Boulder

National Cancer Institute

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference11 articles.

1. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol,2018

2. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib.;Collier;Nat Commun,2017

3. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer;Bauer;Target Oncol,2020

4. First-line lorlatinib or crizotinib in advanced;Shaw;N Engl J Med,2020

5. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial;Shaw;Lancet Oncol,2019

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms;Die Onkologie;2024-08-15

2. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer;Clinical Drug Investigation;2024-07-31

3. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

4. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials;Cancers;2024-07-04

5. Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report;JTO Clinical and Research Reports;2024-07